May 15 (Reuters) - About 20 deaths linked to serious liver dysfunction have been reported in Japan in patients treated with Amgen's rare disease drug Tavneos, according to a safety notice issued by ...
The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.
Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.
Japan's Kissei Pharmaceutical Co. has started urging doctors to refrain from using Tavneos, a drug used to treat rare kidney diseases ...
A Japanese pharmaceutical firm has warned doctors against prescribing a drug for rare autoimmune diseases to new patients following the deaths of 20 people who took it. Kissei Pharmaceutical, which ...
Sales of the problematic Amgen Inc. drug Tavneos resumed late last week in Japan with a new warning label after several patient deaths potentially linked ...
Kissei Pharmaceutical has revised a package insert in Japan for Amgen's rare immune-disease drug Tavneos, saying that serious liver dysfunction could occur. The Japanese pharmaceutical company said ...
June 11 (Reuters) - Amgen said it has signed up a research firm to independently review data for its drug, Tavneos, as it ...
About 20 deaths linked to serious liver dysfunction have been reported in Japan in patients treated with Amgen's rare disease drug Tavneos, according to a safety notice issued by partner Kissei ...
Japanese drugmaker Kissei Pharmaceutical 4547-3.37%decrease; red down pointing triangle said doctors in Japan can again prescribe an Amgen AMGN 0.12%increase; green up pointing triangle rare-disease ...
At least 20 people in Japan who took Amgen's rare disease drug have died, while 22 others developed potentially fatal liver injuries, the Wall Street Journal reported on Friday, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results